Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Engineered Donor Grafts (TregGraft / Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Multiple Cancer Types

This study will evaluate the safety, tolerability, and efficacy of an engineered donor graft ("TregGraft" / "Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
Leukemia, Myelodysplastic Syndrome, Phase I
I
Dholaria, Bhagirathbhai
NCT04013685
VICCCTTP2086

EA2176: Phase 3 Clinical Trial of Carboplatin and Pacliitaxel + / - Nivolumab in Metastatic Anal Cancer Patients

Rectal

This phase 3 trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab together with carboplatin and paclitaxel may help doctors find out if the treatment is better or the same as the usual approach.
Rectal
III
Eng, Cathy
NCT04444921
ECOGGIEA2176

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab / Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

Kidney (Renal Cell)

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab / quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants and (2) pembrolizumab / quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
Kidney (Renal Cell)
III
Beckermann, Kathryn
NCT04736706
VICCURO20101

Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML / MDS After HSCT

Multiple Cancer Types

This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy of administering Mana 312 to subjects with AML / MDS after allogeneic HSCT.
Leukemia, Myelodysplastic Syndrome, Phase I
I
Byrne, Michael
NCT04679194
VICCCTTP20107

Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

Hematologic

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.
Hematologic
I
Dholaria, Bhagirathbhai
NCT03741127
VICCCTT20114

Pembrolizumab Plus Lenvatinib for First-line Advanced / Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

Kidney (Renal Cell)

This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced / metastatic non-clear cell renal cell carcinoma.
Kidney (Renal Cell)
II
Beckermann, Kathryn
NCT04704219
VICCURO20115

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and / or Fedratinib Monotherapy (LIMBER-213)

Multiple Cancer Types

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
Hematologic, Leukemia
II
Mohan, Sanjay
NCT04629508
VICCHEM20129

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

Prostate

The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his / her physician would have already made the decision to treat patient with darolutamide per local standard practice.
Prostate
N/A
Moses, Kelvin
NCT04122976
VICCURO2101

An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.

Multiple Cancer Types

This randomized phase 1b / 2 open-label study will evaluate the efficacy of etrumadenant (AB928) treatment combinations in patients with metastatic colorectal cancer.
Colon, Rectal
I/II
Eng, Cathy
NCT04660812
VICCGIP2113

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients with an IDH2 Mutation

Multiple Cancer Types

This trial studies the side effects of enasidenib and to see how well it works in treating patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with chemotherapy (refractory). Patients must also have a specific genetic change, also called a mutation, in a protein called IDH2. Enasidenib may stop the growth of cancer cells by blocking the mutated IDH2 protein, which is needed for cell growth.
Pediatric Leukemia, Pediatrics
II
Zarnegar-Lumley, Sara
NCT04203316
COGADVL18P1

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: